Introduction
The diurnal and nocturnal pattern of epileptic seizures and influence of the awake and asleep states on seizure presentation have been previously described [1] [2] [3] [4] [5] . Chrono-epileptology takes advantage of this knowledge by tailoring antiepileptic drug (AED) schedules on an individual patient basis, providing higher medication doses at the time of greatest seizure susceptibility, without changing the total daily medication dose. Furthermore, the observation of chronotypical patterns in certain types of epilepsy also can provide clues about sleep-awake behavior, and daily patterns of the seizures, as demonstrated in patients with juvenile myoclonic epilepsy who have tendency to wake up later in the morning and go to bed later [6] . Therefore, ultimately a circadian dysrhythmia may facilitate seizures in these patients, and may also help with antiepileptic drug adjustments [6] .
Studies including several medications suggest a potential effect of differential dosing. In a pediatric study 17 children with nighttime seizures were treated with differential dosing: this study found that 15 (88.2%) patients responded to treatment with !50% seizure reduction [7] . Moreover, 11 (73.3%) of these 15 patients became seizure free [7] . Another study in adults with tonic-clonic seizures and previous use of sub-therapeutic doses of phenytoin and carbamazepine found that administration of a higher percentage of the total daily AED dose in the evening improved seizure control and reduced side effects [8] . These studies included different medications including carbamazepine, phenytoin, levetiracetam, oxcarbazepine and valproic acid [7, 8] . To date, there is limited data on single medication differential dosing trials, or differential dosing trials with clobazam.
We describe a group of patients with refractory epilepsy who used clobazam as an add-on therapy with differential dosing. The main objective of this study was to describe the safety and efficacy of a higher-evening differential dose of clobazam as an add-on therapy.
Methods

Study design
We performed a retrospective case-control study in patients with refractory epilepsy who started clobazam as an add-on AED at a tertiary pediatric epilepsy center between January 2001 and July 2013. This study was approved by the Institutional Review Board at Boston Children's Hospital.
Patients
Differential dose patients were defined as patients with a higher proportion of seizures (>80%) at nighttime or early-morning (6 p.m. to 6 a.m.) and who used more than 50% of the total daily dose of clobazam after 6 p.m.
The control group was defined as patients treated with a nondifferential dose of clobazam as an add-on antiepileptic medication. Differential dose patients and non-differential dose control patients were matched at a 1:2 proportion by age, etiology, seizure type and, presence or absence of brain lesion on MRI exam.
Epilepsy classification
Epilepsy syndrome and seizures types were classified according to International League Against Epilepsy (ILAE) 2010 guidelines [9] .
Seizure frequency
Baseline seizure frequency was calculated as average seizure frequency during three months prior to the introduction of clobazam. Patients with more than 50% seizure reduction at the first follow-up visit were classified as responders. Seizure frequency was calculated using all seizure types during the baseline period and during the period up to the first follow-up.
Data collection
Demographic and seizure data were acquired from clinical charts, and recorded in RedCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN) [10] , a standardized webbased data acquisition tool.
Outcomes
The outcome measure of this study was seizure reduction at first follow-up in patients treated with clobazam differential dosing compared to patients treated with non-differential dosing of clobazam. (Table 2 ). STATA 12.0 (Stata Corp., College Station, TX) was used for statistical analyses. P < 0.05 (two-tailed) was considered statistically significant.
Results
Demographics
From our cohort of 300 patients treated with clobazam as an add-on therapy, 27 (9%) patients were treated with a differential dose regimen. Median age was 9.1 years (SD: 3.9; IQR: 5.5-10.3). Median time interval of the first follow-up was 2.7 months (SD: 4.4, IQR: 1.3-3.8). Etiologic groups in cases were classified as: genetic in 6 (22.2%), structural/metabolic in 12 (44.5%), and unknown in 9 (33.3%) patients (Table 1) .
Clobazam differential dosing
The median clobazam dose at the first follow-up was 0.8 mg/kg/ day (SD: 0.5; IQR: 0.7-1.1 mg/kg/day). The median percentage of the total dose of clobazam administered between 6 p.m. and 6 a.m. was 66.7% (range: 57.1-83.3%). Patients were treated with a median of two concomitant AEDs (IQR: 2-3).
Outcome of differential dosing patients as compared to nondifferential dosing
After adjusting for seizure type, we paired patients with generalized seizures and focal seizures for each medication strategy group. Patients with differential dosing had a five times greater chance of responding to treatment than the control group (Fig. 1) , with the following proportions: median seizure reduction of 75% in differential dose patients (IQR : 60-100%) compared to 50% (IQR: 20-83.3%) seizure reduction in controls (OR; 5; [95% CI: 1.5-16.3]; p < 0.005, Table 3 ). Patients with generalized seizures benefitted the most from differential dosing with a 77.5% (IQR: 63.3-100%) seizure reduction compared to 50% (IQR: 20-93%) in controls (X 2 , p = 0.017, Fig. 2 ). Seizure reduction according to treatment group (differential dose/non-differential dose) is detailed in Table 4 . The total overall daily dose of clobazam at first follow-up was significantly different between the two groups (two-sample t-test, p < 0.05). The median dose of clobazam in differential dosing patients was 0. 
Discussion
We evaluated patients with a predominance of nighttime and early-morning seizures who used clobazam as an add-on therapy with differential dosing, defined as more than 50% of the total daily dose of clobazam administered after 6 p.m. in our study. We compared their seizure control to non-differential dose clobazam patients matched by age, etiology, seizure type, and brain lesion on MRI. We found that differential-dose pediatric patients, treated with clobazam as an add-therapy, had a greater seizure reduction than non-differential dose pediatric patients.
Clobazam has been approved by the Food and Drug Administration (FDA) in 2011 as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome [11] . It is a 1,5-benzodiazepine with anxiolytic and anticonvulsant properties and its major active metabolite is N-desmethyl-clobazam. Clobazam acts by allosteric activation of GABA A receptor, hippocampal up-regulation of GABA transporter 3 (GAT3), augmentation of GAT1, and by increasing glutamate reuptake [11, 12] . It has shown broad efficacy in both focal and generalized seizures, as well as in other associated conditions, such as febrile seizures and hyperekplexia [13] [14] [15] . Clobazam is converted to N-desmethylclobazam, which has about 1/5, the activity of clobazam, contributing to clinical efficacy in long-term clobazam therapy [16] . The estimated mean elimination half-lives (t½) of clobazam and N-desmethylclobazam were 36-42 h and 71-82 h, respectively [12] .
Seizures frequently present in diurnal and nocturnal patterns [5] . The influence of circadian patterns on seizure presentation, as well as the impact of sleep/wake stage, and the 24-h clock on seizures has been shown in several studies, i.e. strong associations between sleep and frontal lobe epilepsies [13] , and upon awakening and juvenile myoclonic epilepsy [14] , among others. More recently, studies detailed the 24-rhythmicity of various seizure types [3] [4] [5] 15] . A study of epilepsy patients with a brain lesion found that temporal lobe epilepsy patients tend to present with seizures during wakefulness, while patients with frontal lobe epilepsy present with seizures during sleep [17] . Another study investigating secondary generalization according to EEG onset (focal or generalized) demonstrated that circadian patterns influence the progression of GTCS, with greater occurrence during sleep, except for GTCS with focal ictal EEG onset which tend to occur more out of sleep [4] . A third study found that hypermotor and automotor seizures occur predominately during the night while clonic, myoclonic, atonic and hypomotor seizures occur during the day [5] . The information provided by circadian seizure studies has provided new avenues to better tailor AED dosing to individual patient's daily seizure presentation, but only few trials utilized this information.
Comparison to available differential dosing studies. The clinical application of chrono-epileptology was demonstrated (2011) [7] in a retrospective study of pediatric patients with nocturnal/early morning seizures who had previously failed regular dosing with AEDs. Using a higher-evening dose of AEDs, seizure reduction by 50% was achieved in 15/17 (88.2%), with seizure freedom in 11/17 (64.7%). Similar outcomes were observed in adults treated with higher-evening doses of carbamazepine and phenytoin [8] . These results corroborate our findings that patients treated with differential dosing may present with higher seizure reduction as compared to controls. In chronotherapy studies, patients were five times more likely to respond to the medication [7, 8] . In our study, the total overall clobazam dose administered at the first follow-up differed between the differential dose and non-differential dose patients, with the former being treated with a higher overall dose, suggesting that overall higher doses of medication were tolerated in the differential dose group. One study in adults adjusted the carbamazepine and phenytoin treatments where the daily total Table 3 Odds ratio (OR) and 95% confidence intervals (CI) for response in use of differential dose (n = 27) and non-differential dose (n = 54) of clobazam. dose was maintained while providing a higher differential dose in the evening. In this study, a significant increase in seizure control with no adverse events was noted [8] . Future prospective trials may need to clarify whether improved outcomes are related to patients tolerating a higher dose of medication with reduced side effects or whether timing of the medication contributes to improved outcomes, and we speculate that both aspects may play a role. Chronopharmacokinetic changes in the plasma level of the drug and pharmacokinetic variables (absorption, distribution, metabolism and excretion) have been described in rodents treated with carbamazepine and valproate. These studies demonstrated the effect of daily protein levels variance and light exposure on AED pharmacokinetics [18, 19] . Human studies have demonstrated the role of the daily distribution of plasma protein on valproate [20] and carbamazepine [21] pharmacokinetics, and the influence of meals [22] , red blood cell concentration [23] , and daytime [24] on valproate distribution. Additionally, a concept of relative 'drug holiday' by decreasing the medication dose, with subsequently improved responsiveness has been suggested to account for the treatment effect, that can likely not solely be explained by increase in the AED level. Forthcoming studies applying continuous and fluctuating drug delivery system concepts, that release of the bioactive component of AEDs to circadian pattern and other biomarkers may improve care of epilepsy patients in the future.
Results need to be interpreted in the setting of data acquisition. Patients in this study were selected from a pool of patients with refractory epilepsy who used clobazam as add-on therapy. In general, these patients received polytherapy, and we were not able to discriminate the effect of each medication. The small sample size did not allow us to answer specific questions, such as the impact of clobazam on specific etiologies. Due to the retrospective nature of the study, we were not able to select a control group that also had predominately nighttime/earlymorning seizures and maintain AEDs stable over time. Dose regimens were different for both groups however, our observations can be corroborated by a meaningful chronotherapeutic study that concluded that administration of most or all doses at nighttime, presented a better seizure control, achieved therapeutic drug level, as well as reduced toxicity in the group with toxic levels [8] . In order to minimize the effect of daily seizure patterns we matched the groups by age, etiology, MRI lesion and seizure type. Furthermore, our study was influenced by selection bias and inherent information bias leading us to analyze our results taking into account these possible drawbacks. Despite these limitations, we were able to observe greater efficacy on generalized over focal seizures with clobazam differential dosing in patients with a predominance of late-evening and early-morning seizures as compared to non-differential dosing of clobazam.
Conclusion
A higher-evening differential dose of clobazam, based upon times of highest seizure susceptibility improved seizures in patients with predominantly nighttime and early-morning seizures. Chronotherapy tailored to the patients' seizure susceptibility patterns may improve care in epilepsy patients without increasing the side-effects.
